Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fight against novel coronavirus: A perspective of medicinal chemists
Sk. Abdul Amin, Tarun Jha
European Journal of Medicinal Chemistry (2020) Vol. 201, pp. 112559-112559
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
Sk. Abdul Amin, Suvankar Banerjee, Kalyan Ghosh, et al.
Bioorganic & Medicinal Chemistry (2020) Vol. 29, pp. 115860-115860
Open Access | Times Cited: 175
An Updated Review of Computer‐Aided Drug Design and Its Application to COVID‐19
Arun Bahadur Gurung, M. Ajmal Ali, Joongku Lee, et al.
BioMed Research International (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 160
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19
Ilaria Vicenti, Maurizio Zazzi, Francesco Saladini
Expert Opinion on Therapeutic Patents (2021) Vol. 31, Iss. 4, pp. 325-337
Open Access | Times Cited: 112
Molnupiravir: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 4, pp. 455-460
Open Access | Times Cited: 77
Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery
Muhammed Tılahun Muhammed, Esin Aki
Letters in Drug Design & Discovery (2022) Vol. 21, Iss. 3, pp. 480-495
Closed Access | Times Cited: 77
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
Xiaojing Pang, Wei Xu, Yang Liu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115491-115491
Open Access | Times Cited: 56
SARS‐CoV‐2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?
Stefano Pascarella, Massimo Ciccozzi, Davide Zella, et al.
Journal of Medical Virology (2021) Vol. 93, Iss. 12, pp. 6551-6556
Open Access | Times Cited: 94
Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
Hasanain Abdulhameed Odhar
Bioinformation (2020) Vol. 16, Iss. 3, pp. 236-244
Open Access | Times Cited: 86
Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs
Amgad M. Rabie
New Journal of Chemistry (2020) Vol. 45, Iss. 2, pp. 761-771
Closed Access | Times Cited: 81
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Ching‐Chi Lee, Chih‐Chia Hsieh, Wen‐Chien Ko
Antibiotics (2021) Vol. 10, Iss. 11, pp. 1294-1294
Open Access | Times Cited: 76
An update review of emerging small-molecule therapeutic options for COVID-19
Dengke Tian, Yuzhi Liu, Chengyuan Liang, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 137, pp. 111313-111313
Open Access | Times Cited: 62
Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
Ashley Jia Wen Yip, Zheng Yao Low, Vincent Chow, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1345-1345
Open Access | Times Cited: 38
Chemical-informatics approach to COVID-19 drug discovery: Exploration of important fragments and data mining based prediction of some hits from natural origins as main protease (Mpro) inhibitors
Kalyan Ghosh, Sk. Abdul Amin, Shovanlal Gayen, et al.
Journal of Molecular Structure (2020) Vol. 1224, pp. 129026-129026
Open Access | Times Cited: 64
First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery
Sk. Abdul Amin, Suvankar Banerjee, Samayaditya Singh, et al.
Molecular Diversity (2021) Vol. 25, Iss. 3, pp. 1827-1838
Open Access | Times Cited: 49
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2
Devendra Singh Negi, Irshad Ahmad
European Journal of Medicinal Chemistry (2021) Vol. 213, pp. 113157-113157
Open Access | Times Cited: 45
Synthesis of Functionalized 2′,5‐Oxo‐spiro[furan‐2,3′‐indoline]‐3‐carboxylate Derivatives as Antiproliferative Agents: ADMET Studies, and Molecular Docking against P2Y12 Inhibitors
Mohd Asif, Mohammad Saquib, Abdul Rahman Khan, et al.
ChemistrySelect (2023) Vol. 8, Iss. 11
Closed Access | Times Cited: 15
Accurate prediction of dynamic protein–ligand binding using P‐score ranking
Peter E. G. F. Ibrahim, Fabio Zuccotto, Ulrich Zachariae, et al.
Journal of Computational Chemistry (2024) Vol. 45, Iss. 20, pp. 1762-1778
Closed Access | Times Cited: 5
Analysis of Structures of SARS-CoV-2 Papain-like Protease Bound with Ligands Unveils Structural Features for Inhibiting the Enzyme
Ann Varghese, Jie Liu, Bailang Liu, et al.
Molecules (2025) Vol. 30, Iss. 3, pp. 491-491
Open Access
Decoding SARS‐CoV‐2 Inhibition: Insights From Molecular Dynamics Simulation of Condensed Amino Thiourea Scaffold Small Molecules
Xiaoli Shen, Hao Zhang, Pengyin Zhang, et al.
Journal of Cellular Biochemistry (2025) Vol. 126, Iss. 2
Closed Access
Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic
Chengyuan Liang, Nan Hui, Yuzhi Liu, et al.
Phytomedicine Plus (2021) Vol. 1, Iss. 2, pp. 100027-100027
Open Access | Times Cited: 34
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies
Mohitosh Biswas, Nares Sawajan, Thanyada Rungrotmongkol, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 22
Biflavonoids from Rhus succedanea as probable natural inhibitors against SARS-CoV-2: a molecular docking and molecular dynamics approach
Kiran Bharat Lokhande, Neelu Nawani, Swamy K. Venkateswara, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 40, Iss. 10, pp. 4376-4388
Open Access | Times Cited: 38
Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives
Anna Pawełczyk, Lucjusz Zaprutko
Future Medicinal Chemistry (2020) Vol. 12, Iss. 19, pp. 1743-1757
Open Access | Times Cited: 32
Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
Sk. Abdul Amin, Suvankar Banerjee, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2021) Vol. 215, pp. 113294-113294
Open Access | Times Cited: 29
Novel piperazine based compounds as potential inhibitors for SARS-CoV-2 Protease Enzyme: Synthesis and molecular docking study
Alaa Z. Omar, Tawfik M. Mosa, Samer K. El-sadany, et al.
Journal of Molecular Structure (2021) Vol. 1245, pp. 131020-131020
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top